Foradil, Formoterol Newswire

Foradil, Formoterol Newswire

Comprehensive Real-Time News Feed for Foradil, Formoterol (generic).

Results 1 - 20 of 223 in Foradil, Formoterol (generic)

  1. Research Report and Overview on Bronchitis Treatment Market, 2016-2026Read the original story

    Yesterday | Emailwire.com

    Future Market Insights has announced the addition of the 'Bronchitis Treatment Market: Global Industry Analysis and Opportunity Assessment 2016-2026" report to their offering. The chronic bronchitis is defined as the inflammation of the bronchi that lasts for more than 3 months for consecutive 2 years.

    Comment?

  2. Millar says Wiggins' TUE drugs should be bannedRead the original story w/Photo

    Tuesday Sep 20 | Cycling News

    Former pro David Millar told the Telegraph this week that the corticosteroid Bradley Wiggins used with a Therapeutic Use Exemption should be banned, and that he "couldn't fathom" a doctor prescribing it for a rider before competition. Speaking with the Telegraph in light of recent revelations about Wiggins' use of the drug before the 2011 and 2012 Tours de France and before the 2013 Giro d'Italia, Millar said the corticosteroid was the "most potent" performance enhancing drug he used in his own career.

    Comment?

  3. Wiggins: Leinders had no part in TUE applicationsRead the original story w/Photo

    Saturday Sep 17 | Cycling News

    Bradley Wiggins has released a second statement in relation to the leaked medical information stemming from the Fancy Bears' hack into WADA's Anti-Doping Administration and Management System , stating that Dr Geert Leinders played no part in his TUE applications, and that he did not look to mislead the public over his previous 'no injection' comments. Tsar Team also known as 'Fancy Bears' released their second round of data from its hack of WADA's Anti Doping Administration and Management System on Friday, with Wiggins one of 29 athletes included, alongside fellow Tour de France winner Chris Froome.

    Comment?

  4. Wiggins spokesperson on WADA leak: 'There's nothing new here'Read the original story w/Photo

    Thursday Sep 15 | Cycling News

    Bradley Wiggins has responded to the leak of his medical information by hackers of the World Anti Doping Agency's systems with a statement issued through a spokesperson saying: "There's nothing new here." Tsar Team also known as 'Fancy Bear' released a second round of data from its hack of WADA's Anti Doping Administration and Management System , with Wiggins one of 29 athletes concerned, alongside fellow Tour de France winner Chris Froome.

    Comment?

  5. Froome has 'no issues' with leaked TUE data from WADA hackRead the original story w/Photo

    Thursday Sep 15 | Cycling News

    Team Sky has said that it followed due process in applying for the therapeutic use exemptions for Chris Froome and Bradley Wiggins that were highlighted by Russian cyber-hackers on Wednesday . Froome has said that he has "no issues" with the leak of information.

    Comment?

  6. Bradley Wiggins not concerned by WADA hack releaseRead the original story w/Photo

    Thursday Sep 15 | Yahoo!

    As part of a hack on WADA, Bradley Wiggins appears to have had personal records released, but a spokesperson is unconcerned. As part of a hack on WADA, Bradley Wiggins appears to have had personal records released, but a spokesperson is unconcerned.

    Comment?

  7. Current issueRead the original story

    Thursday Sep 15 | P&T Community

    Escalating drug prices have seeded interest in value-based purchasing, but confusion and controversy have slowed the Centers for Medicare and Medicaid Services, state agencies, and private insurers from pursuing the potential savings. As researchers devise ever-more-costly therapies and P&T committees try to balance innovation and affordability, managed care experts warn that the struggle to pay the bills could threaten the sustainability of the nation's inefficient health care system.

    Comment?

  8. Bespak to supply AstraZeneca components for LAMA/LABA inhalerRead the original story w/Photo

    Wednesday Sep 14 | In-PharmaTechnologist.com

    AstraZeneca has struck a supply deal with Bespak for components in pressurised metered-dose inhalers for a recently approved COPD treatment. In April, the US Food and Drug Administartion approved Bevespi Aerosphere, a fixed-dose dual bronchodilator combining glycopyrrolate and formoterol fumarate - a long-acting muscarinic antagonist and long-acting beta-2 agonist - for patients with chronic obstructive pulmonary disease .

    Comment?

  9. Consort Medical Release: New Scale-Up And Commercial Supply AgreementRead the original story

    Sunday Sep 11 | BioSpace

    Consort Medical plc , is pleased to announce the successful signing of a significant new commercial supply agreement for Bespak's proprietary respiratory devices. AstraZeneca AB and Bespak have agreed to enter into a multi-year agreement for the scale-up and supply of Bespak's proprietary pressurised metered dose inhaler valves and actuators.

    Comment?

  10. Theravance Biopharma Highlights Positive Results From Pivotal Phase 3 ...Read the original story

    Wednesday Sep 7 | BioSpace

    Statistically Significant Benefits in Lung Function, Health-Related Quality of Life and Annual Rate of Exacerbations Observed for Closed Triple as Compared to Symbicort Turbohaler Theravance Biopharma Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Agreement With Innoviva Theravance Biopharma, Inc. today announced that GlaxoSmithKline plc and Innoviva, Inc. have presented additional positive data from the pivotal Phase 3 FULFIL study of the Closed Triple in patients with chronic obstructive pulmonary disease .

    Comment?

  11. Theravance Biopharma Touts Significant Data from Pivotal Phase III Fulfil StudyRead the original story

    Wednesday Sep 7 | BioSpace

    Statistically Significant Benefits in Lung Function, Health-Related Quality of Life and Annual Rate of Exacerbations Observed for Closed Triple as Compared to Symbicort Theravance Biopharma Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Agreement With Innoviva : TBPH ) today announced that GlaxoSmithKline plc and Innoviva, Inc. have presented additional positive data from the pivotal Phase 3 FULFIL study of the Closed Triple in patients with chronic obstructive pulmonary disease .

    Comment?

  12. Bronchitis Treatment Market Forecast and Segments, 2016-2026Read the original story w/Photo

    Wednesday Sep 7 | SBWire

    The chronic bronchitis is defined as the inflammation of the bronchi that lasts for more than 3 months for consecutive 2 years. The bronchi are the tubes which carry air in to the lungs.

    Comment?

  13. GSK presents positive results from phase III Fulfil study of closed...Read the original story

    Tuesday Sep 6 | PressReleasePoint

    GlaxoSmithKline plc and Innoviva, Inc. today announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease , at the European Respiratory Society International Congress taking place in London this week. The FULFIL study was designed to evaluate the effects of once daily FF/UMEC/VI compared with twice daily SymbicortA TurbohalerA in patients with advanced COPD.

    Comment?

  14. Bronchitis Treatment Market Forecast and Segments, 2016-2026Read the original story w/Photo

    Thursday Sep 1 | PR-inside.com

    Future Market Insights has announced the addition of the "Bronchitis Treatment Market: Global Industry Analysis and Opportunity Assessment 2016-2026" report to their offering. The chronic bronchitis is defined as the inflammation of the bronchi that lasts for more than 3 months for consecutive 2 years.

    Comment?

  15. AstraZeneca's Symbicort shows comparable safety profile to budesonide alone in long-term safety studyRead the original story w/Photo

    Thursday Sep 1 | Seeking Alpha

    Results from a five-year 11,693-subject safety study comparing AstraZeneca's asthma med SYMBICORT Inhalation Aerosol to budesonide alone showed a comparable risk of serious asthma-related events and lower risk of asthma exacerbations. Specifically, the trial showed statistical non-inferiority of SYMBICORT to budesonide in the time to first asthma-related event and a 16.5% lower risk of asthma exacerbations versus budesonide.

    Comment?

  16. AstraZeneca PLC's Long-Acting Asthma Drug Symbicort Safe in Two TrialsRead the original story

    Wednesday Aug 31 | BioSpace

    AstraZeneca today announced results from the SYMBICORTA Inhalation Aerosol LABA safety study showing patients with controlled and uncontrolled asthma had a comparable risk of serious asthma-related events and a lower risk of asthma exacerbations when formoterol was combined with budesonide versus budesonide alone. The study compared the safety of formoterol, a LABA, used in combination with budesonide, an inhaled corticosteroid -the two active therapies in SYMBICORT pressurized metered dose inhaler -against budesonide to evaluate the risk of serious asthma-related events.

    Comment?

  17. Combination drug therapy safe, effective in treating asthma patientsRead the original story w/Photo

    Wednesday Aug 31 | Medical News

    A post-marketing safety study mandated by the U.S. Food and Drug Administration has shown that a combination drug therapy for the treatment of asthma is safe and effective. "Our study showed no significant increase in serious adverse events in the combination therapy," said Stephen Peters, M.D., Ph.D., professor of pulmonary, critical care, allergy and immunologic diseases at Wake Forest Baptist Medical Center and lead author of the study.

    Comment?

  18. Study shows combination drug therapy for asthma patients is safeRead the original story w/Photo

    Wednesday Aug 31 | PhysOrg Weblog

    A post-marketing safety study mandated by the U.S. Food and Drug Administration has shown that a combination drug therapy for the treatment of asthma is safe and effective. "Our study showed no significant increase in serious adverse events in the combination therapy," said Stephen Peters, M.D., Ph.D., professor of pulmonary, critical care, allergy and immunologic diseases at Wake Forest Baptist Medical Center and lead author of the study.

    Comment?

  19. AstraZeneca Announces SYMBICORT Demonstrated Comparable Risk of...Read the original story w/Photo

    Wednesday Aug 31 | Freshnews

    AstraZeneca today announced results from the SYMBICORTA Inhalation Aerosol LABA safety study showing patients with controlled and uncontrolled asthma had a comparable risk of serious asthma-related events and a lower risk of asthma exacerbations when formoterol was combined with budesonide versus budesonide alone. The study compared the safety of formoterol, a LABA, used in combination with budesonide, an inhaled corticosteroid -the two active therapies in SYMBICORT pressurized metered dose inhaler -against budesonide to evaluate the risk of serious asthma-related events.

    Comment?

  20. Vectura's Asthma Med Flutiform Flunks Final Late-Stage StudyRead the original story

    Monday Aug 29 | BioSpace

    Mundipharma carried out this Phase III study to support a filing to expand the approved indication for the regular treatment of asthma of flutiform A in Europe to include chronic obstructive pulmonary disease . Mundipharma is currently undertaking an analysis of the trial's other endpoints but has indicated that the primary endpoint result will not allow it to make a regulatory filing for the COPD indication in Europe.

    Comment?